BB Biotech Initiates Position in Eupraxia Pharmaceuticals
BB Biotech reported building a new, small investment position in Eupraxia Pharmaceuticals as part of its portfolio updates.
Stocks · News reference
Eupraxia Pharmaceuticals shares are trading higher after the company announced updated Phase 1b/2a RESOLVE data showing the long duration of response, high remission rates and tolerability of EP-104GI for the treatment of Eosinophilic Esophagitis.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Eupraxia Pharmaceuticals to Participate at Upcoming Conferences and Host a Virtual Analyst Day
Eupraxia Pharmaceuticals announced its participation in the Craig Hallum Biotech Catalyst Virtual Conference and the hosting of a virtual analyst day on October 22, 2026.
Eupraxia Reaches Its Target Enrollment Of 120 Patients In Phase 2b Placebo-Controlled Blinded Portion Of RESOLVE Trial
Eupraxia reached its target enrollment of 120 patients in the Phase 2b placebo-controlled blinded portion of the RESOLVE trial The Company has a statistical team who are doing periodic reviews of the unblinded data to
Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences
Eupraxia Pharmaceuticals announced that three abstracts from its Phase 1b/2 RESOLVE trial of EP-104GI for treating eosinophilic esophagitis (EoE) have been accepted for presentation at the ACG 2026 Annual Scientific Meeting in Nashville (October 9-14) and UEG Week 2026 in Barcelona (October 17-20). The presentations will showcase data on improvements in dysphagia and histopathological features persisting over 52 weeks during dose escalation. Phase 2b interim data is expected in December 2026.
HC Wainwright & Co. Reiterates Buy on Eupraxia Pharmaceuticals, Maintains $11 Price Target
Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals announced positive 52-week data from its Phase 1b/2a RESOLVE trial of EP-104GI for treating eosinophilic esophagitis (EoE). The highest dose cohorts demonstrated durable symptom responses with 64% of patients maintaining clinical remission at 52 weeks, meaningful histologic improvements, and a favorable safety profile with no serious adverse events or oropharyngeal candidiasis reported. The company plans to report Phase 2b interim data in December 2026.